Abstract
Isocitrate lyase plays a key role for survival of Mycobacterium tuberculosis in the latent form during a chronic stage of infection. This enzyme is important for M. tuberculosis during steady stage growth when it converts isocitrate to succinate and glyoxylate. Then, the glyoxylate is condensed with acetyl-CoA to form malate by malate synthase. The carbon conserving glyoxylate pathway has not been observed in mammals; therefore, it has been determined as a potential drug target for discovery of a new antituberculosis agent. Novel active molecules should shorten the duration of therapy, prevent resistance development and eliminate latent disease. The review summarizes recent progresses in isocitrate lyase inhibitors, overviews structural analogues of several metabolic intermediates (3- nitropropionate, 3-bromopyruvate, itaconate, itaconic anhydride), peptide inhibitors, and recently developed inhibitors with various chemical structures. The largest inhibitory activity against isocitrate lyase (IC50 of 0.10 ± 0.01 μM) and concomitantly a significant antimycobacterial activity has been presented by fluoroquinolone derivative 1-cyclopropyl-7-[3,5-dimethyl-4-(3-nitropropanoyl)piperazin- 1-yl]-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid, which has incorporated 3-nitropropionyl group as one of the structural analogue of succinate, a metabolic intermediate.
Keywords: Drug target, enzyme inhibition, glyoxylate pathway, isocitrate lyase, tuberculosis, Mycobacterium tuberculosis
Current Medicinal Chemistry
Title:Advances in Mycobacterial Isocitrate Lyase Targeting and Inhibitors
Volume: 19 Issue: 36
Author(s): M. Kratky and J. Vinsova
Affiliation:
Keywords: Drug target, enzyme inhibition, glyoxylate pathway, isocitrate lyase, tuberculosis, Mycobacterium tuberculosis
Abstract: Isocitrate lyase plays a key role for survival of Mycobacterium tuberculosis in the latent form during a chronic stage of infection. This enzyme is important for M. tuberculosis during steady stage growth when it converts isocitrate to succinate and glyoxylate. Then, the glyoxylate is condensed with acetyl-CoA to form malate by malate synthase. The carbon conserving glyoxylate pathway has not been observed in mammals; therefore, it has been determined as a potential drug target for discovery of a new antituberculosis agent. Novel active molecules should shorten the duration of therapy, prevent resistance development and eliminate latent disease. The review summarizes recent progresses in isocitrate lyase inhibitors, overviews structural analogues of several metabolic intermediates (3- nitropropionate, 3-bromopyruvate, itaconate, itaconic anhydride), peptide inhibitors, and recently developed inhibitors with various chemical structures. The largest inhibitory activity against isocitrate lyase (IC50 of 0.10 ± 0.01 μM) and concomitantly a significant antimycobacterial activity has been presented by fluoroquinolone derivative 1-cyclopropyl-7-[3,5-dimethyl-4-(3-nitropropanoyl)piperazin- 1-yl]-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid, which has incorporated 3-nitropropionyl group as one of the structural analogue of succinate, a metabolic intermediate.
Export Options
About this article
Cite this article as:
Kratky M. and Vinsova J., Advances in Mycobacterial Isocitrate Lyase Targeting and Inhibitors, Current Medicinal Chemistry 2012; 19 (36) . https://dx.doi.org/10.2174/0929867311209066126
DOI https://dx.doi.org/10.2174/0929867311209066126 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Baculovirus for Eukaryotic Protein Display
Current Gene Therapy Catalytic Epoxidation and syn-Dihydroxylation Reactions in Steroid Chemistry
Current Organic Chemistry Epithelial-Mesenchymal Transition as a Therapeutic Target for Prevention of Ocular Tissue Fibrosis
Endocrine, Metabolic & Immune Disorders - Drug Targets Glycomics: Relevance for Personalized Medicine
Current Pharmacogenomics and Personalized Medicine The Role of Cytokines in Atopic Asthma
Current Medicinal Chemistry Evaluation of the in vivo Safety Profiles of Rictor Inhibition Using a Zebrafish Model
Current Pharmaceutical Design Smoking and Eye Pathologies. A Systemic Review. Part I. Anterior Eye Segment Pathologies
Current Pharmaceutical Design Biologics: An Update and Challenge of Their Pharmacokinetics
Current Drug Metabolism Genomic and Pharmacogenomic Biomarkers of Parkinson’s Disease
Current Drug Metabolism Development of Yeast Molecular Display Systems Focused on Therapeutic Proteins, Enzymes, and Foods: Functional Analysis of Proteins and its Application to Bioconversion
Recent Patents on Biotechnology Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules
Current Medicinal Chemistry Targeting Angiogenesis in Head and Neck Cancer
Current Cancer Drug Targets Pharma-metabolomics in Neonatology: is it a Dream or a Fact?
Current Pharmaceutical Design Plasma Rich in Growth Factors Enhances Wound Healing and Protects from Photo-oxidative Stress in Dermal Fibroblasts and 3D Skin Models
Current Pharmaceutical Biotechnology Mangiferin – a Bioactive Xanthonoid, not only from Mango and not just Antioxidant
Mini-Reviews in Medicinal Chemistry Animal Mitochondria: Evolution, Function, and Disease
Current Molecular Medicine Key miRNAs in Modulating Aging and Longevity: A Focus on Signaling Pathways and Cellular Targets
Current Molecular Pharmacology Pharmacokinetics and In Vivo Fate of Drug Loaded Chitosan Nanoparticles<sup>++</sup>
Current Drug Metabolism The Role of Oxidative Stress in Smoking-Related Diseases
Mini-Reviews in Organic Chemistry Healthcare Management During A Pandemic: The Other Side of the Coin for the Treatment of COVID-19 Infection
Endocrine, Metabolic & Immune Disorders - Drug Targets